Carbon-11 Radiopharmaceuticals - Radiopharmacy Aspects

  • C. Halldin
  • S-O. Nilsson
Chapter
Part of the Developments in Nuclear Medicine book series (DNUM, volume 22)

Abstract

Examples of the routine production of some 11C-labelled PET radiopharmaceuticals which have been set up for patient application are discussed. This includes recommendations and general guidelines for safety and procedures for the a) preparation of the radionuclide and the primary precursors b) synthesis of some secondary precursors c) synthesis, purification, analysis and membrane filtration of some selected 11C-receptor ligands and d) metabolite studies. Furthermore, radiopharmacy aspects as quality assurance and quality control are discussed. The general quality criterias described are the following: a) radionuclidic purity b) chemical purity c) radiochemical purity d) specific radioactivity e) pharmaceutical quality and f) stability and shelf-life.

Keywords

Positron Emission Tomography High Performance Liquid Chromatography Radiochemical Purity Methyl Iodide Ethyl Iodide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Axelson S., Långström B. and Matsson O. (1987) A new carbon isotope effect as a mechanistic probe. Determination of primary 11C/14C kinetic isotope effect in a N-alkylation of a tertiary amine. J. Am. Chem. Soc. 109, 7233.Google Scholar
  2. Berger G., Maziere M., Sastre J. and Comar D. (1980) Carrier-free 11C -formaldehyde: an approach. J. Lab. Comp. Radiopharm. 17, 59.Google Scholar
  3. Bryant R. (1989) The Pharmaceutical Quality Control Handbook.Aster Publ. Corp. Eugene. Oregon.Google Scholar
  4. Christman D.R., Finn R.D., Karlstrom K.I. and Wolf A.P. (1975) The production of ultra high activity 11C-labeled hydrogen cyanide, carbon monoxide and methane via the 14N(p, a)11C reaction. Int. J. Appl. Radiat. Isot. 26, 435.Google Scholar
  5. Comar D., Maziere M. and Crouzel C. (1974) Synthése et métabolisme de molécules radiopharmaceutiques marquées au carbone-11-I-iodométhylate de chlorpromazine-11C. In: Radiopharmaceuticals and Labelled Compounds. IAEA, Vienna. 1, 461Google Scholar
  6. Commision of the European Communities III/B/6. (1990) The rules governing medical products in the european community, Vol IV; Guide to good manufacturing practice for medicinal products. (Draft supplementary guidelines for the manufacture of radiopharmaceuticals.) Nr. III/3973/89-EN (April 1990) Commision of the European Communities, Bruxelles.Google Scholar
  7. Crouzel C., Amano R. and Fournier D. (1987a) Synthesis of carbon-11 labelled diazomethane. Appl. Radiat. Isot. 38, 669.Google Scholar
  8. Crouzel C., Långström B., Pike V.W. and Coenen H.H. (1987b) Recommendations for a practical production of [11C]methyl iodide. Appl. Radiat. Isot. 38, 601.Google Scholar
  9. DeJesus O.T., van Moffart G.J.C. and Friedman A.M. (1987) Synthesis of [11C]SCH 23390 for dopamine D1 receptor studies. (1987) Appl. Radiat. Isot. 38, 345.Google Scholar
  10. Ehrin E., Farde L., de Paulis T., Eriksson L., Greitz T., Johnström P., Litton J-E., Nilsson L., Sedvall G., Stone-Elander S. and Ögren S-O. (1985) Preparation of 11C -labelled raclopride, a new potent dopamine receptor anatgonist: prelininary PET studies of cerebral dopamine receptors in the monkey. Int. J. Appl. Radiat. Isot. 36, 269.PubMedGoogle Scholar
  11. Farde L., Hall H., Ehrin E. and Sedvall G. (1986) Quantitative analysis of dopamine D2 receptor binding in the living human brain by positron emission tomography. Science 231, 258.PubMedGoogle Scholar
  12. Farde L., Halldin C., Stone-Elander S. and Sedvall G. (1987) Analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C -raclopride. Psychopharmacology 92, 278.PubMedGoogle Scholar
  13. Farde L., Pauli S., Hall H., Eriksson L., Halldin C., Högberg T., Nilsson L., Sjögren I. and Stone-Elander S. (1988a) Stereoselective binding of 11C -raclopride in living human brain - a search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology 94, 471.PubMedGoogle Scholar
  14. Farde L., Wiesel F-A., Halldin C. and Sedvall G. (1988b) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 45, 71.PubMedGoogle Scholar
  15. Farde L., Eriksson L., Blomquist G. and Halldin C. (1989) Kinetic analysis of 11C- raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J. Cer. Blood Flow Met. 9, 696.Google Scholar
  16. Farde L., Wiesel F-A., Stone-Elander S., HaUdin C., Nordström A-L., Hall H. and Sedvall G. (1990) D2-dopamine receptors in neuroleptic-naive schizophrenic patients - aPET-study with [11C]raclopride. Arch. Gen. Psychiatry. 47, 213.PubMedGoogle Scholar
  17. Fowler J.S. and Wolf A.P. (1986) In Positron Emission Tomography and Autoradiography: Principals and Applications for the Brain and Heart. (Eds Phelps M., Mazziotta J. and Schelbert H.) pp. 391–450. Raven Press, New York.Google Scholar
  18. Frost J.J. and Wagner H.N. (1990) Quantitative imaging. Raven Press, p 118.Google Scholar
  19. Hall H., Köhler C., Gawell L., Farde L. and Sedvall G. (1988) Raclopride, a new selective ligand for the dopamine-D2 receptors. Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 12, 559.Google Scholar
  20. Halldin C. and Långström B. (1984) Synthesis of 11C-labelled aldehydes. Acta Chem. Scand. 38, 1.Google Scholar
  21. Halldin C., Stone-Elander S., Farde L., Ehrin E., Fasth K-J., Långström B. and Sedvall G. (1986) Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Appl. Radiat. Isot. 37, 1039.Google Scholar
  22. Halldin C., Stone-Elander S., Thorell J-O., Persson A. and Sedvall G. (1988) 11C-Labelling of Ro 15–1788 in two different positions, and also 11C-labelling of its main metabolite Ro 15–3890, for PET studies of benzodiazepine receptors. Appl. Radiat. Isot. 39, 993.Google Scholar
  23. Halldin C., Farde L., Högberg T., Hall H. and Sedvall G. (1990) Carbon-11 labelling of eticlopride in two different positions - a selective high-affinity ligand for the study of dopamine D-2 receptors using PET. Appl. Radiat. Isot. 41, 669.Google Scholar
  24. Halldin C., Farde L., Högberg T., Hall H., Ström P., Ohlberger A. and Solin O. (1991a) A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Nucl. Med. Biol. (In press).Google Scholar
  25. Halldin C., Swahn C-G., Farde L., Litton J-E. and Sedvall G. (1991b) Determination of (11C)SCH 23390 and its radioactive metabolites in plasma by HPLC. Eur. J. Nucl. Med. (Submitted).Google Scholar
  26. Hantraye P., Kaijima M., Prenant C., Giubert B., Sastre J., Crouzel M., Naquet R., Comar D. and Maziere D. (1984) Central type benzodiazepine binding sites: a positron emission tomography study in the baboons brain. Neurosci. Lett. 48, 115.PubMedGoogle Scholar
  27. Hyttel J. (1983) SCH 23390 - the first slective dopamine Dl antagonist. Eur. J. Pharmacol. 91, 153.PubMedGoogle Scholar
  28. Iorio L.C. (1981) SCH 23390. A benzazepine with a atypical effects on dopaminergic systems. The Pharmacologist 23, 136.Google Scholar
  29. Köhler C., Hall H., Ögren S-O. and Gawell L. (1985) Specific in vitro and in vivo binding of [3H]raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem. Pharmac. 34, 2251.Google Scholar
  30. Loch C, Hantraye P., Khalili-Varasteh M., Maziere B., Delforge J., Brouillet E., Syrota A. and Maziere B. (1990) C-11 Flumazenil metabolism: analysis of unchanged ligand in baboon plasma. J. Nucl. Med. 31, 897.Google Scholar
  31. Luthra S.K., Turton D.R., Price G., Ahier R., Martin F., Hume S. and Cremer J. (1990) The determination of unchanged [11C]diprenorpfiine, [11C]L-deprenyland [11C]raclopride in plasma by HPLC. J. Lab. Comp. Radiopharm. (in press).Google Scholar
  32. Långström B. and Lundqvist H. (1976) The preparation of [11C]methyl iodide and its use in the synthesis of [methyl-11C]L-methionine. Appl. Radiat. Isot. 27, 357.Google Scholar
  33. Långström B., Antoni G., Gullberg P., Halldin C., Någren K., Rimland A. and Svard H. (1986) The synthesis of [1–11C]-labelled ethyl, propyl, butyl and isobutyl iodides and examples of alkylation reactions. Appl. Radiat. Isot. 37, 1141.Google Scholar
  34. Långström B., Antoni G., Gullberg P., Halldin C., Malmborg P., Någren K., Rimland A. and Svärd H. (1987) Synthesis of L- and D-[methyl-11C]methionine. J. Nucl. Med. 28, 1037.PubMedGoogle Scholar
  35. Maziere M., Prenant C., Sastre J., Crouzel M, Comar D., Hantraye P., Kaijima M, Guibert B. and Naquet R. (1983) 11C-Ro 15–1788 et 11C-flunitrazepam, deux coordinats pour letude par tomographic par positons des sites de liasion des benzodiazepines. CR Acad Sci (Paris) 296: 871.Google Scholar
  36. Maziere M., Hantraye P., Prenant C., Sastre J. and Comar D. (1984) Synthesis of ethyl 8- fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo[l,5 a][l,4]benzo-diazepine-3- carboxylate (Ro 15- 1788–11C): A specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int. J. Appl. Radiat. I sot. 35, 973.Google Scholar
  37. Meyer G-J., Coenen H.H., Waters S.L., Långström B., Cantineau R., Strijckmans K., Vaalburg W., Halldin C., Crouzel C. and Maziere B. (1991) Task group on “Quality assurance and quality control of short-lived radiopharmaceuticals” EEC Concerted Action on PET, Investigations of Cellular Regeneration and Degeneration (D. Comar).Google Scholar
  38. Muhr C., Bergström M., Lundberg P.O., Bergström K. and Långström B. (1986) In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography. Acta Radiol. Synopsis. 369, 406.Google Scholar
  39. Persson A., Ehrin E., Eriksson L., Farde L., Hedström C.G., Litton J.E., Mindus P. and Sedvall G. (1985) Imaging of 11C-labelled Ro 15–1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. J. Psychiat. Res. 19, 609.PubMedGoogle Scholar
  40. Persson A., Pauli S., Halldin C., Stone-Elander S., Farde L., Sjögren I. and Sedvall G. (1989a) Saturation analysis of specific 11C-Ro 15–1788 binding to the human neocortex using positron emission tomography. Human Psychopharmacology 4, 21.Google Scholar
  41. Persson A., Pauli S., Swahn C-G., Halldin C. and Sedvall G. (1989b) Cerebral uptake of 11C- Rp 15–1788 and its acid metabolite 11C-Rp 15–3890; PET study in healthy volunteers. Human Psychopharmacology. 4, 215.Google Scholar
  42. Pike V.W., Kensett M.J., Turton D.R., Waters S.L. and Silvester D.J. (1990) Labelled agents for PET studies of the dopaminergic system - some quality assurance methods, experience and issues. Appl Radiat. Isot. 41, 483.Google Scholar
  43. Ravert. H.T., Wilson. A.A., Dannals R.F., Wong D.F. and Wagner H.N. (1987) Radiosynthesis of a selective dopamine D-1 receptor antagonist: (+)-7-chloro-8-hydroxy-3-[11C]methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine([11C]SCH 3390). Appl. Radiat. Isot. 38, 305.Google Scholar
  44. Reiffers S., Vaalburg W., Wiegman T., Wynberg H. and Woldring M.G. (1980) Carbon-11 labelled methyllithium as methyl donating agent: the addition to 17-keto steroids. Int. J. Appl. Radiat. Isot. 31, 535.Google Scholar
  45. Rinne J.O., Lahinen A., Någren K., Bergman J., Solin O., Haaparanta M., Ruotsalainen U. and Rinne U.K. (1990) PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson’s disease. J. Neurosci. Res. 27, 494.PubMedGoogle Scholar
  46. Roeda D. and Westera G. (1981) A UV-induced on-line synthesis of 11C-phosgen and the preparation of some of its derivatives. Int. J. Appl Radiat. Isot. 32, 931.Google Scholar
  47. Samson Y., Hantraye P., Baron J-C., Soussaline F., Comar D. and Maziere M. (1985) Kinetics and displacement of [11C]Ro 15–1788, a benzodiazepine antagonist, studied in human brain in vivo by positron emission tomography. Eur. J. Pharmacol. 110, 247.PubMedGoogle Scholar
  48. Savic I., Roland P., Sedvall G., Persson A., Pauli S. and Widen L. (1988) In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 16, 863.Google Scholar
  49. Sedvall G., Farde L., Stone.Elander S. and Halldin C. (1986) Dopamine Dl-receptor binding in the living human brain. In: Breese G.R., Creese I. (eds) Neurobiology of central DI- dopamine receptors. Plenum, New York, 119.Google Scholar
  50. Schoeps K-O., Halldin C., Stone-Elander S., Långström B. and Greitz T. (1988) Preparation of 11C-nitromethane and an example of its use as a radiolabeling precursor. J. Lab. Comp. Radiopharm. 25, 749.Google Scholar
  51. Schoeps K-O., Stone-Elander S. and Halldin C. (1989) On-line synthesis of 11C-nitroalkanes. Appl. Radiat. Isot. 40, 261.Google Scholar
  52. Shinotoh H., Yamasaki T., Inoue O., Itoh T., Suzuki K., Hashimoto K., Tateno Y. and Ikehira H. (1986) Visualization of specific binding sites of benzodiazepine in human brain. J. Nucl. Med. 27, 1593.PubMedGoogle Scholar
  53. Sharp J.R., ed., (1983) Guide to Good Pharmaceutical Manufactering Practice. Publ. by Her Majesty’s Stationary Office, London.Google Scholar
  54. Swahn C-G., Persson A. and Pauli S. (1989) Metabolism of the benzodiazepine antagonist 11C-Ro 15–1788 after intravenous administration in man. Human Psychopharmacology. 4, 297.Google Scholar
  55. Swahn C-G., Farde L., Nordström A-L., Halldin C. and Sedvall L. (1991) Analysis of unchanged compound in human plasma after administration of three 11C-labelled dopamine antagonists, raclopride, SCH 23390 and N-methylspiroperidol. Human Psychopharmacology (submitted).Google Scholar
  56. Suhara T., Fukuda H., Inoue O., Itoh T., Suzuki K., Yamasaki T. and Tateno Y. (1991) Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology 103, 41.PubMedGoogle Scholar
  57. Suzuki K., Inoue O., Hashimoto K., Yamasaki T., Kuchiki M. and Tamate K. (1985) Computer-controlled large scale production of high specific activity [11C]Ro 15–1788 for PET studies of benzodiazepine receptors. Int. J. Appl. Radiat. Isot. 36, 971.Google Scholar
  58. Tang D.Y., Lipman A., Meyer G-J., Wan C-N. and Wolf A.P. (1979) 11C-Labelled octanol and benzaldehyde. J. Lab. Comp. Radiopharm. 16, 435.Google Scholar
  59. Vera-Ruiz H., Marcus C.S., Pike V.W., Coenen H.H., Fowler J.S., Meyer G-J., Cox P.H., Vaalburg W., Cantineau R., Helus F. and Lambrecht R.M. (1990) Report of an International Atomic Energy Agency’s Advisory Group Meeting on “Quality control of cyclotron-produced radiopharmaceuticals”. Nucl. Med. Biol. 17, 445.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • C. Halldin
  • S-O. Nilsson

There are no affiliations available

Personalised recommendations